Joseph P Reo

US Patent:

20080020055, Jan 24, 2008

Filed:

Jun 1, 2007

Appl. No.:

11/756881

Inventors:

David Monteith - Pittstown NJ, US
John O'Mullane - Mountain Lakes NJ, US
Joseph Reo - Lakeland TN, US
Robert Nowak - New Providence NJ, US
Jiansheng Wan - Springfield NJ, US
Mohammed Kabir - Lakeland TN, US
Malaz Abutarif - North Brunswick NJ, US
Glenn Fritz - Arlington TN, US

International Classification:

A61K 31/137
A61K 31/4545
A61K 9/14
A61P 11/02
A61P 31/16
A61P 37/00

US Classification:

424497000, 424490000, 514290000, 514653000

Abstract:

The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s). The pharmaceutical composition can further comprise one or more additional therapeutically active agents selected from one or more of the group consisting of antihistamines, analgesics, anti-pyretics, and non-steroidal anti-inflammatory agents. The invention also discloses methods of administering phenylephrine via the colon, thereby increasing the bioavailable amount of therapeutically active unconjugated phenylephrine relative to the total phenylephrine in the plasma.

US Patent:

20090280160, Nov 12, 2009

Filed:

Dec 4, 2008

Appl. No.:

12/328429

Inventors:

David Monteith - Pittstown NJ, US
John O'Mullane - Mountain Lakes NJ, US
Joseph P. Reo - Lakeland TN, US
Dennis Nelson - Memphis TN, US
Jiansheng Wan - Warren NJ, US
Xiaoming Chen - Westfield NJ, US
Mohammed A. Kabir - Lakeland TN, US

International Classification:

A61K 9/70
A61K 9/00
A61K 9/14
A61K 9/12
A61K 31/137
C07C 215/54

US Classification:

424443, 424400, 424489, 424 45, 514653, 564355

Abstract:

Pharmaceutical compositions comprising phenylephrine or a pharmaceutically acceptable salt thereof and methods for administering the pharmaceutical compositions wherein the composition is formulated for systemic absorption of phenylephrine that avoids first pass metabolism. The compositions of the invention are formulated to be applied to oral mucosa of an animal to allow for enhanced systemic delivery of therapeutically active form of phenylephrine.

US Patent:

20150290147, Oct 15, 2015

Filed:

Dec 16, 2014

Appl. No.:

14/571890

Inventors:

- Memphis TN, US
John O'Mullane - Mountain Lakes NJ, US
Robert T. Nowak - New Providence NJ, US
Jiansheng Wan - Springfield NJ, US
Mohammed A. Kabir - Lakeland TN, US
Joseph P. Reo - Lakeland TN, US
Malaz A. Abutarif - North Brunswick NJ, US
Glenn E. Fritz - Arlington TN, US

Assignee:

MSD Consumer Care, Inc. - Memphis TN

International Classification:

A61K 31/137
A61K 47/12
A61K 31/4545
A61K 47/38
A61K 9/50
A61K 9/16

Abstract:

The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s). The pharmaceutical composition can further comprise one or more additional therapeutically active agents selected from one or more of the group consisting of antihistamines, analgesics, anti-pyretics, and non-steroidal anti-inflammatory agents. The invention also discloses methods of administering phenylephrine via the colon, thereby increasing the bioavailable amount of therapeutically active unconjugated phenylephrine relative to the total phenylephrine in the plasma.